What is uniQure's market cap?

uniQure (QURE) has a market capitalization of $2.6B and trades on NASDAQ.

What is uniQure's revenue and profitability?

uniQure generated $18.7M in trailing twelve-month revenue with a net loss of $252.2M, representing a net margin of -1350.7%. Gross margin stands at 92.5%, with free cash flow of -$161.5M. These figures are based on the Q2 2026 filing.

Who are uniQure's competitors?

uniQure's key competitors include Sarepta Therapeutics, Voyager Therapeutics, Tenaya Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does uniQure partner with?

uniQure's notable partners include CSL Behring.

What subsidiaries does uniQure have?

uniQure's subsidiaries include uniQure Inc., Corlieve Therapeutics.

Where is uniQure headquartered?

uniQure is headquartered in Netherlands and employs approximately 480 people. It has been publicly traded since 2014.

uniQure

QURE

uniQure N.V. is a biotechnology company focused on the development of innovative gene therapies for patients with rare and devastating genetic diseases.

Market cap

$2.63B+231%

Revenue$18.7M+30.2%

Net income-$252.2M-26.7%

Free cash flow-$161.5M+7.3%

EPS (diluted)-$4.01-2.3%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q2 2026 report

July 29, 2026

Revenue$5.8MBeat by $391.9K EPS-$1.22Miss by $0.40

Read the full report

Next report

Date not yet announced

Financials

Q2 2026

Income statement

See full

Revenue$5.8M+11.0%

Gross profit$5.5M+19.2%

Operating income-$52.2M-19.0%

Net income-$81.1M-115%

EPS (diluted)-$1.22-76.8%

Balance sheet

See full

Cash & equivalents$413.0M+62.8%

Total debt$62.8M-5.8%

Total equity$324.1M+8,195%

Total assets$985.1M+68.4%

Cash flow

See full

Operating cash flow-$28.6M+28.4%

CapEx$472.0K+81.5%

Free cash flow-$29.0M+27.7%

Valuation & ratios

Valuation

See full

Market cap$2.63B+231%

Enterprise value$2.28B+260%

P/S140.7×+83.5×

Profitability

See full

Gross margin92.5%+4.6pp

Operating margin-1,071.5%-90.6pp

Net margin-1,350.7%-35.3pp

FCF margin-864.7%-194pp

Returns & leverage

See full

Debt / equity0.2×—

Current ratio10×0.0×

Segments

By segment

See full

Single Reportable$5.8M+11.0%

Competitors

By market cap

uniQure$2.6B+220%

Sarepta Therapeutics, Inc.$1.7B+23.2%

Taysha Gene Therapies, Inc.$1.6B+128%

Neurogene$690.7M+123%

Benitec Biopharma Inc.$397.8M+37.5%

Voyager Therapeutics, Inc.$186.7M+3.2%

Tenaya Therapeutics, Inc.$167.0M+31.6%

PAS

Passage Bio, Inc.$14.8M-32.5%

By revenue growth

uniQure+30.2%

Sarepta Therapeutics, Inc.+9.9%

Taysha Gene Therapies, Inc.+3.4%

By net margin

Sarepta Therapeutics, Inc.4.64%-38.4pp

uniQure-1,350.73%+37.3pp

Taysha Gene Therapies, Inc.-1,738.4%-537pp

Profile

uniQure N.V. is a biotechnology company focused on the development of innovative gene therapies for patients with rare and devastating genetic diseases. The company leverages its proprietary technology platform to design and deliver single-administration treatments intended to provide long-term or curative clinical benefits.

Competitive position

A pioneer in the gene therapy space with one of the first FDA-approved gene therapy products and a robust clinical pipeline targeting neurodegenerative conditions.

GeographiesUnited States, European Union

Customer segmentsPatients with rare genetic diseases, Specialized healthcare institutions

Business modelR&D intensive, IP licensing, Biopharmaceutical development

SuppliersPlasmid and vector manufacturers, Specialized laboratory equipment providers, Clinical research organizations

CustomersSpecialty pharmacies, Hospitals, Academic medical centers

CountryNetherlands

Listed2014

Employees480.0

CEOMatthew Kapusta

SectorHealthcare

IndustryBiotechnology

Websiteuniqure.com

FilingsSEC EDGAR

Ask your AI about uniQure.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is uniQure's market cap?: uniQure (QURE) has a market capitalization of $2.6B and trades on NASDAQ.
What is uniQure's revenue and profitability?: uniQure generated $18.7M in trailing twelve-month revenue with a net loss of $252.2M, representing a net margin of -1350.7%. Gross margin stands at 92.5%, with free cash flow of -$161.5M. These figures are based on the Q2 2026 filing.
Who are uniQure's competitors?: uniQure's key competitors include Sarepta Therapeutics, Voyager Therapeutics, Tenaya Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does uniQure partner with?: uniQure's notable partners include CSL Behring.
What subsidiaries does uniQure have?: uniQure's subsidiaries include uniQure Inc., Corlieve Therapeutics.
Where is uniQure headquartered?: uniQure is headquartered in Netherlands and employs approximately 480 people. It has been publicly traded since 2014.